199 related articles for article (PubMed ID: 37349676)
1. PSMD8 can serve as potential biomarker and therapeutic target of the PSMD family in ovarian cancer: based on bioinformatics analysis and in vitro validation.
Li X; Li X; Hu Y; Liu O; Wang Y; Li S; Yang Q; Lin B
BMC Cancer; 2023 Jun; 23(1):573. PubMed ID: 37349676
[TBL] [Abstract][Full Text] [Related]
2. Annexin A8 can serve as potential prognostic biomarker and therapeutic target for ovarian cancer: based on the comprehensive analysis of Annexins.
Gou R; Zhu L; Zheng M; Guo Q; Hu Y; Li X; Liu J; Lin B
J Transl Med; 2019 Sep; 17(1):275. PubMed ID: 31474227
[TBL] [Abstract][Full Text] [Related]
3. The Prognostic Significance of Proteasome 26S Subunit, Non-ATPase (PSMD) Genes for Bladder Urothelial Carcinoma Patients.
Salah Fararjeh A; Al-Khader A; Al-Saleem M; Abu Qauod R
Cancer Inform; 2021; 20():11769351211067692. PubMed ID: 34992336
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive analysis of PSMD family members and validation of PSMD9 as a potential therapeutic target in human glioblastoma.
Li Y; Liu X; Zhao F; Zhao Z; Li X; Wang J; Huang B; Chen A
CNS Neurosci Ther; 2024 Feb; 30(2):e14366. PubMed ID: 37485655
[TBL] [Abstract][Full Text] [Related]
5. Increased Expression of
Zou R; Xu H; Li F; Wang S; Zhu L
DNA Cell Biol; 2021 Jan; 40(1):36-60. PubMed ID: 33180631
[TBL] [Abstract][Full Text] [Related]
6. MRPL15 is a novel prognostic biomarker and therapeutic target for epithelial ovarian cancer.
Xu H; Zou R; Li F; Liu J; Luan N; Wang S; Zhu L
Cancer Med; 2021 Jun; 10(11):3655-3673. PubMed ID: 33934540
[TBL] [Abstract][Full Text] [Related]
7. Expression profiles and prognostic values of BolA family members in ovarian cancer.
Zhu M; Xiao S
J Ovarian Res; 2021 Jun; 14(1):75. PubMed ID: 34078439
[TBL] [Abstract][Full Text] [Related]
8. A bioinformatics analysis of the clinicopathological and prognostic significance of
Zheng HC; Ren DH; Zhang CY; Chen Y; Zhang L
J Obstet Gynaecol; 2023 Dec; 43(1):2216280. PubMed ID: 37227120
[TBL] [Abstract][Full Text] [Related]
9. Determination of Potential Therapeutic Targets and Prognostic Markers of Ovarian Cancer by Bioinformatics Analysis.
Zhang J; Huang S; Quan L; Meng Q; Wang H; Wang J; Chen J
Biomed Res Int; 2021; 2021():8883800. PubMed ID: 33829065
[TBL] [Abstract][Full Text] [Related]
10. Prognostic and immune infiltration signatures of proteasome 26S subunit, non-ATPase (PSMD) family genes in breast cancer patients.
Xuan DTM; Wu CC; Kao TJ; Ta HDK; Anuraga G; Andriani V; Athoillah M; Chiao CC; Wu YF; Lee KH; Wang CY; Chuang JY
Aging (Albany NY); 2021 Nov; 13(22):24882-24913. PubMed ID: 34839279
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of Epithelial Splicing Regulatory Protein 1 in Metastatic Lesions of Serous Ovarian Carcinoma Correlates with Poor Patient Prognosis.
Lu X; Li R; Wang X; Guo Q; Wang L; Zhou X
Cancer Biother Radiopharm; 2022 Nov; 37(9):850-861. PubMed ID: 34495766
[No Abstract] [Full Text] [Related]
12. Molecular Analysis of Prognosis and Immune Infiltration of Ovarian Cancer Based on Homeobox D Genes.
Chen B; Gao C; Wang H; Sun J; Han Z
Comput Math Methods Med; 2022; 2022():3268386. PubMed ID: 36213580
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of SEC61G in lung adenocarcinoma: a comprehensive study based on bioinformatics and in vitro validation.
Zheng Q; Wang Z; Zhang M; Yu Y; Chen R; Lu T; Liu L; Ma J; Liu T; Zheng H; Li H; Li J
BMC Cancer; 2021 Nov; 21(1):1216. PubMed ID: 34774014
[TBL] [Abstract][Full Text] [Related]
14. Biological and prognostic value of ETV5 in high-grade serous ovarian cancer.
Zhang L; Fu R; Liu P; Wang L; Liang W; Zou H; Jia W; Tao L
J Ovarian Res; 2021 Nov; 14(1):149. PubMed ID: 34736492
[TBL] [Abstract][Full Text] [Related]
15. SLC7A2 serves as a potential biomarker and therapeutic target for ovarian cancer.
Sun T; Bi F; Liu Z; Yang Q
Aging (Albany NY); 2020 Jul; 12(13):13281-13296. PubMed ID: 32647070
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of trophoblast cell surface antigen 2 as an independent marker for a poor prognosis and as a potential therapeutic target in epithelial ovarian carcinoma.
Xu N; Zhang Z; Zhu J; Xu L; Li Y; Duan L; Mao Y; Li H
Int J Exp Pathol; 2016 Apr; 97(2):150-8. PubMed ID: 27127000
[TBL] [Abstract][Full Text] [Related]
17. Quantitative assessment and clinical relevance of kallikrein-related peptidase 5 mRNA expression in advanced high-grade serous ovarian cancer.
Gong W; Liu Y; Seidl C; Diamandis EP; Kiechle M; Drecoll E; Kotzsch M; Magdolen V; Dorn J
BMC Cancer; 2019 Jul; 19(1):696. PubMed ID: 31307411
[TBL] [Abstract][Full Text] [Related]
18. High ATP6V1B1 expression is associated with poor prognosis and platinum‑based chemotherapy resistance in epithelial ovarian cancer.
Han GH; Yun H; Chung JY; Kim JH; Cho H
Oncol Rep; 2023 May; 49(5):. PubMed ID: 36999629
[TBL] [Abstract][Full Text] [Related]
19. Mortalin is a distinct bio-marker and prognostic factor in serous ovarian carcinoma.
Xu M; Jin T; Chen L; Zhang X; Zhu G; Wang Q; Lin Z
Gene; 2019 May; 696():63-71. PubMed ID: 30776464
[TBL] [Abstract][Full Text] [Related]
20. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
